Where Will Recursion Pharmaceuticals Be in 5 Years?

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...
The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
GEN

StockWatch: After $50M from Nvidia, Investors Bullish on Recursion

The appetites of biotech investors for companies expanding in artificial intelligence show no signs of slowing any time soon, as reflected by the stock surge enjoyed by Recursion Pharmaceuticals (RXRX ...
Hosted on MSN

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...
Business Insider

The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...
Reuters

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival ...